U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07521449) titled 'Effects of Phosphatidylserine and DHA on Cognitive Performance in Children With ADHD' on April 03.
Brief Summary: This study aimed to evaluate the effects of different phosphatidylserine (PS) formulations, with or without docosahexaenoic acid (DHA), on cognitive performance in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) or presenting with clinically significant subthreshold ADHD symptoms.
A total of 45 medication-naive children aged 10-14 years were randomly assigned to one of four groups: placebo, PS capsule (PS + DHA), PS sachet (PS without DHA), or PS Plus capsule (higher-dose PS + DHA). The interven...